This new series of monthly podcasts will feature information on a wealth of emerging topics in the field of Gynecological Oncology. Each month one of our Editor's will have an in-depth conversation with the Author of a Editor's Choice article as well as the Author of the commentary/editorial that ac…
Editor’s Choice: Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study Editorial: Prevention of Gestational Trophoblastic Neoplasia with Actinomycin -D at the time of evacuation: A Matter of Routine Practice or Reserve for Special Circumstances?
Editor’s Choice: Clinical trial enrollment during first course of gynecologic cancer treatment and survival Editorial: Clinical trials are not the solution to inequities in cancer care
Editor’s Choice: Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma Editorial: Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma Hosted by:Warner Huh, MD, Deputy Editor of Gynecologic OncologyFeaturing: Tullia Rushton, MD Beryl L. Manning-Geist, MD
Editor’s Choice: The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study Editorial: Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit – That's a relief!
Editor’s Choice: Implementation of a financial navigation program in gynecologic oncology Editorial: Financial toxicity: moving from describing the problem toward developing interventions Hosted by:Diane Yamada, MDFeaturing: Katharine M. Esselen, MDMargaret Liang, MD
Editor’s choice: The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma Editorial: Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment? Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic OncologyFeaturing: Mohamed Elshaikh, MDBeriwal Sushil MD
Editor’s choice: Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva Editorial: Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic Oncology Featuring: Dr Lilian T. Gien, MD, MSc, FRCSC, University of Toronto, Canada Dr Brenna Swift, MD, FRCSC, MSc, MASc, University of Toronto, Canada Dr Scott Glaser, MD, City of Hope, USA
Editor’s choice: Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists Editorial: Who you gonna call? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring:M. Dwight Chen, MD, Palo Alto Foundation Medical Group/Sutter HealthConnor C. Wang, MD, Northwestern University Feinberg School of MedicineEmma Barber, MD, MS, Northwestern University Feinberg School of Medicine
Editor’s choice: Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists Editorial: Who you gonna call? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring:M. Dwight Chen, MD, Palo Alto Foundation Medical Group/Sutter HealthConnor C. Wang, MD, Northwestern University Feinberg School of MedicineEmma Barber, MD, MS, Northwestern University Feinberg School of Medicine
Reviews: 2023 changes to FIGO endometrial cancer staging: Counterpoint; 2023 FIGO staging system for endometrial cancer: The evolution of the revolution Editorial: 2023 FIGO staging for endometrial cancer, a look at both sides of the coin Hosted by: Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic Oncology Featuring: Dr. Alexander Olawaiye, MD, University of Pittsburgh School of Medicine, USA Dr. David Gaffney, MD-PhD, University of Utah, USA Dr. Mario Leitao, Jr., MD, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, USA
Editor’s Choice Paper:Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo study Editorial:Sentinel lymph node biopsy in high-risk endometrial cancer: The dénouement Hosted by:Gregg Nelson, MD, Social Media Editor of Gynecologic OncologyFeaturing:Sarah M. Bjørnholt, MD, Aarhus University Hospital, DenmarkSean Dowdy, MD, Mayo Clinic, USA
Editor’s Choice Paper: Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers Editorial:The importance of family-focused care in the setting of advanced gynecological cancersHosted by:Sean Dowdy, MD, Associate Editor of Gynecologic OncologyFeaturing:Rachel A. Pozzar, PhD, RN, Dana Farber Cancer Institute and Harvard Medical SchoolAllison J. Applebaum, PhD, Caregivers Clinic, Memorial Sloan Kettering Cancer Center
Editor’s Choice Paper: Associations between modifiable lifestyle factors and health-related quality of life among endometrial carcinoma survivors - A cross-sectional study Hosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic OncologyFeaturing:Ane Gerda Z. Eriksson, MD, Oslo University Hospital, NorwayS. J. Kitson, MD, University of Manchester, UK
Editor’s Choice Paper: Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer Hosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Kathleen N. Moore, MD, GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center
Editor’s Choice Paper: Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis? Editorial: Universal thromboprophylaxis in ovarian cancer patients before and after surgery? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Amanika Kumar, MD, Mayo Clinic Laura Havrilesky, MD, Duke University
Editor’s Choice Paper: Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis? Editorial: Universal thromboprophylaxis in ovarian cancer patients before and after surgery? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Amanika Kumar, MD, Mayo Clinic Laura Havrilesky, MD, Duke University
Editor's Choice Papers: Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancerEditorial: Universal testing – Should it be that hard? Probably. If you're doing it rightHosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring: Bhavana Pothuri, MD,NYU Perlmutter Cancer CenterLeigha Senter, MS, CGC, The Ohio State University College of Medicine
Editor's Choice Papers: Detection of endometrial cancer using tampon-based collection and methylated DNA markersEditorial: Early detection of endometrial cancerHosted by:Dineo Khabele, MD, Associate Editor of Gynecologic Oncology Featuring:Jamie N. Bakkum-Gamez, MD, Mayo ClinicJonathan C. Dudley, MD, The Johns Hopkins University School of Medicine
Editor's Choice Papers: Detection of endometrial cancer using tampon-based collection and methylated DNA markersEditorial: Early detection of endometrial cancerHosted by:Dineo Khabele, MD, Associate Editor of Gynecologic Oncology Featuring:Jamie N. Bakkum-Gamez, MD, Mayo ClinicJonathan C. Dudley, MD, The Johns Hopkins University School of Medicine
TKI Toxicities: A Society of Gynecologic Oncology Podcast Moderator:Róisín O'Cearbhaill, MD, Gynecologic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York Speakers: BJ Rimel, MD, Gynecologic Oncologist, Cedars-Sinai Medical CenterErin Crane, MD, MPH, Gynecologic Oncologist, Levine Cancer InstituteVicky Makker, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center Jennifer MacDonald, PharmD, Oncology Clinical Pharmacy Specialist, Medical University of South Carolina Róisín O'Cearbhaill, MD, is joined by BJ Rimel, MD, Erin Crane, MD, MPH, Vicky Makker, MD, and Jennifer McDonald, PharmD, to review the clinical management of tyrosine kinase inhibitors (TKIs) in gynecologic cancers with consideration for dose adjustments and modifications. The speakers discuss the optimal management of commonly encountered toxicities, such as hypertension and hypothyroidism, that are associated with several of the TKIs. They also highlight management strategies, patient reference materials and anticipatory prescriptions for antihypertensives, antidiarrheals, and antiemetics. The podcast includes two patient cases that delve into information about the differences in toxicities between lenvatinib and pazopanib, hypertension and which drugs to use in which order (both starting dose and dose adjustments), and medical access and lab intervals. These practical clinical pearls in managing toxicities aim to guide practitioners on how best to use these drugs to treat gynecologic cancers. This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology. Additional Resources: Tyrosine kinase inhibitor toxicities: A Society of Gynecologic Oncology review and recommendations Download audio Browse all Gynecologic Oncology audio
Moderator: Róisín O'Cearbhaill, MD, Gynecologic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York Featuring: BJ Rimel, MD, Gynecologic Oncologist, Cedars-Sinai Medical Center Erin Crane, MD, MPH, Gynecologic Oncologist, Levine Cancer Institute Vicky Makker, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center Jennifer MacDonald, PharmD, Oncology Clinical Pharmacy Specialist, Medical University of South Carolina
Hosted by: Amanda Nickles Fader, MD, Associate Editor of Gynecologic Oncology Featuring: Gregg Nelson, MD, University of Calgary Sean Dowdy, MD, Mayo Clinic College of Medicine Olle Ljungqvist, MD, Örebro University Hospital Editor's Choice Papers: Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update
Editor's Choice Papers: Enhanced recovery after surgery (ERAS reg) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update Editorial: Gynecologic oncology surgery – Ready for the next step in ERASHosted by:Amanda Nickles Fader, MD, Associate Editor of Gynecologic Oncology Featuring: Gregg Nelson, MD, University of CalgarySean Dowdy, MD, Mayo Clinic College of MedicineOlle Ljungqvist, MD, Orebro University Hospital
Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Ann Oluloro, MD, MPH, University of Washington Eloise Chapman-Davis, MD, Weill Cornell Medicine Editor's Choice Papers: What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women
Hosted by: David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring: Stephanie V. Blank, MD, Icahn School of Medicine at Mount Sinai Warner K. Huh, MD, FACOG, FACS, University of Alabama Birmingham Editor's Choice Papers: Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report
Editor's Choice Papers: Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report Editorial: “The times they are a-changin'” – And how are we managing?Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring: Stephanie V. Blank,MD, Icahn School of Medicine at Mount SinaiWarner K. Huh, MD, FACOG, FACS, University of Alabama Birmingham
Editor's Choice Papers: Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level – A Memorial Sloan Kettering Cancer Center study Editorial: Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a “pelvic” surgeon Hosted by:Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic Oncology Featuring: Ryan M. Kahn MD,FACOG, Memorial Sloan Kettering Cancer Center Dennis Chi, MD, Memorial Sloan Kettering Cancer CenterProf Christina Fotopoulou, Imperial College London, UK
Hosted by: Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic Oncology Featuring: Ryan M. Kahn MD, FACOG, Memorial Sloan Kettering Cancer Center Dennis Chi, MD, Memorial Sloan Kettering Cancer Center Prof Christina Fotopoulou, Imperial College London, UK Editor's Choice Papers: Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level – A Memorial Sloan Kettering Cancer Center study
Hosted by: Wendy R. Brewster, MD, PhD, Deputy Editor of Gynecologic Oncology Featuring: Turgay Ayer, Georgia Institute of Technology Tara Castellano, MD, Louisiana State University HSC Isabel C. Scarinci, PhD, MPH, University of Alabama at Birmingham Editor's Choice Papers: Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer Editorial: Targeting our efforts: the contribution of an open-access tool to assess geographic distribution of recurrent and metastatic cervical cancer
Hosted by: Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring: Jennifer Mueller MD, Memorial Sloan Kettering Cancer Center Emad Matanes MD, Rambam Medical Center Emma Rossi MD, Duke University Medical Center Editor's Choice Papers: Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon? Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia? Editorial: Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment?
Moderator: Kari Hacker, MD, PhD, Gynecologic Oncologist, New York University Langone Health Speakers: Christine Walsh, MD, MS, Gynecologic Oncologist, University of Colorado Carolyn McCourt, MD, Gynecologic Oncologist, Washington University School of Medicine Kari Hacker, MD, PhD, is joined by Christine Walsh, MD, MS, and Carolyn McCourt, MD, to review basic molecular classification as well as more complex biomarkers in endometrial cancer. They discuss how testing can be utilized to inform patient prognosis and to guide second line systemic treatment decisions. They also highlight several ongoing trials investigating treatment strategies based on molecular features, the results of which will help clinicians make better therapeutic decisions, resulting in better outcomes for patients with endometrial cancer. This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology. Additional Resources: Molecular testing for endometrial cancer: An SGO clinical practice statement
Editor's Choice Papers: Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon? Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia? Editorial: Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment? Hosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring: Jennifer Mueller MD, Memorial Sloan Kettering Cancer CenterEmad Matanes MD, Rambam Medical CenterEmma Rossi MD, Duke University Medical Center
Hosted by: Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring:Brittany A. Davidson, MD, Duke UniversityDavid M. Kushner, MD, UW School of Medicine and Public Health Article: SGO and the elephant that is still in the room: Wellness, burnout and gynecologic oncology
Hosted by: Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring: Brittany A. Davidson, MD, Duke University, David M. Kushner, MD, UW School of Medicine and Public Health Article: SGO and the elephant that is still in the room: Wellness, burnout and gynecologic oncology
Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology and Author of the editorial Featuring: David O'Malley, MD, The Ohio State University Editor's Choice Paper: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma Editorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data
Hosted by: Amanda Nickles Fader, MD, Associate Editor of Gynecologic Oncology Featuring: David M. Gershenson, MD, The University of Texas MD Anderson Cancer Center Charlie Gourley, MD, Nicola Murray Centre for Ovarian Cancer Research Editor's Choice Paper: Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival Editorial: Low grade serous ovarian cancer: Unpicking drivers of outcome
Hosted by: Amanda Nickles Fader, MD, Associate Editor of Gynecologic OncologyFeaturing:David M. Gershenson, MD, The University of Texas MD Anderson Cancer CenterCharlie Gourley, MD, Nicola Murray Centre for Ovarian Cancer ResearchEditor's Choice Paper: Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival Editorial: Low grade serous ovarian cancer: Unpicking drivers of outcome
Hosted by: S. Diane Yamada, MD, Deputy Editor of Gynecologic Oncology Featuring: Maaike Oonk, MD, University Medical Center Groningen, University of Groningen, The Netherlands Akila Viswanathan, MD, MPH, Johns Hopkins Medicine Editor's Choice Paper: Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe Editorial:When is it safe to omit contralateral groin management in unilateral sentinel node-positive early stage vulvar cancer?
Hosted by: Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring: Mariam M. AlHilli, MD Gynecologic Oncologist, Cleveland Clinic, Cleveland Ohio Amanika Kumar, MD, Mayo Clinic Division of Gynecologic Surgery, Rochester, Minnesota Editor's Choice Paper: Preoperative assessment using the five-factor modified frailty index: A call for standardized preoperative assessment and prehabilitation services in gynecologic oncology Editorial: Answering the call: Are we ready for action on frailty in gynecologic oncology?
Hosted by: David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring: Joshua G. Cohen, MD, Gynecologic Oncologist, City of Hope Orange County Fumiko Chino, MD, Affordability Working Group, Radiation Oncologist, Memorial Sloan Kettering Cancer Center Editor's Choice Paper: Insurance-based disparities and risk of financial toxicity among patients undergoing gynecologic cancer operations Editorial: Financial toxicity of surgical treatment for gynecological cancer: A growing malignancy
Hosted by: Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic Oncology Featuring: Pr Alejandra Martinez, Institut Universitaire du Cancer de Toulouse Oncopole Jill Tseng, MD, UC Irvine Health Editor's Choice Paper: The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer Editorial: Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles
Hosted by: Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic Oncology Featuring: Pr Alejandra Martinez, Institut Universitaire du Cancer de Toulouse Oncopole Jill Tseng, MD, UC Irvine Health Editor's Choice Paper: The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer Editorial: Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles
Hosted by: Jose Alejandro Rauh-Hain, MD, MPH, Associate Editor of Gynecologic Oncology Featuring: Steven S. Coughlin, MD, Augusta University Daniel Addison, MD, The Ohio State University Wexner Medical Center Editor's Choice Paper: Cardiovascular conditions and obesity among gynecologic cancer survivors: Results from the 2020 behavioral risk factor surveillance system survey Editorial: The intersection of gynecologic cancer, obesity, and cardiovascular disease
Moderator: Leslie Clark, MD, Gynecologic Oncologist, University of North Carolina in Chapel Hill Speakers: Róisín O'Cearbhaill, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center Ramez Eskander, MD, Gynecologic Oncologist, University of California San Diego Additional Resources: Immunotherapy toxicities: An SGO clinical practice statement
Hosted by: S. Diane Yamada, MD, Deputy Editor of Gynecologic Oncology Featuring: Jessica N. McAlpine, MD, University of British Columbia G. Larry Maxwell, MD, FACOG, COL(ret) USA, Inova Health System Editor's Choice Paper: Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification Editorial: The ProMisE of uniform care for endometrial cancer patients
Hosted by: John Farley, MD, Associate Editor of Gynecologic Oncology Featuring: Catherine H. Watson, MD, Vanderbilt University Medical Center Larissa Alejandra Meyer, MD MPH, The University of Texas MD Anderson Cancer Center Editor's Choice Paper: Reducing non-surgical readmissions on a gynecologic oncology service Editorial: Our dual responsibility of improving quality and questioning the metrics: Reflections on 30-day readmission rate as a quality indicator
Hosted by: Sean C. Dowdy, MD, Associate Editor of Gynecologic Oncology Featuring: Sara Elisabeth Sponholtz, MD, PhD, University of Southern Denmark Mario M. Leitao, Jr., MD, Memorial Sloan-Kettering Cancer Center Editor's Choice Paper: SENTIREC - The sentinel node mapping in women with cervical cancer study - Patient-reported early lymphedema and its impact on quality of life Editorial: The end of routine lymphadenectomy for the treatment of cervical cancer is rapidly approaching
Hosted by: John Farley, MD, Associate Editor of Gynecologic Oncology Featuring: Catherine H. Watson, MD, Vanderbilt University Medical Center Larissa Alejandra Meyer, MD MPH, The University of Texas MD Anderson Cancer Center Editor's Choice Paper: Reducing non-surgical readmissions on a gynecologic oncology service Editorial: Our dual responsibility of improving quality and questioning the metrics: Reflections on 30-day readmission rate as a quality indicator
Hosted by: Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic Oncology Featuring: Elizabeth Swisher, MD, UW Medicine Jonathan A Ledermann MD FRCP FMedSci Professor of Medical Oncology, UCL Cancer Institute Editor's Choice Paper: Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study Editorial: Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?
Hosted by: David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring: Kristin Weeks, MD/PhD candidate, University of Iowa David Shalowitz, MD, MSHP, Wake Forest School of Medicine Center Editor's Choice Paper: Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients Editorial: Defining the essential role of the gynecologic oncologist in rural ovarian cancer care delivery
Hosted by: Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic Oncology Featuring: Elizabeth Swisher, MD, UW Medicine Jonathan A Ledermann, MD FRCP FMedSci Professor of Medical Oncology, UCL Cancer Institute Editor's Choice Paper: Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study Editorial: Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?